Mirna Therapeutics Inc. (MIRN) Hits New 12-Month Low at $3.48
Mirna Therapeutics Inc. (NASDAQ:MIRN) shares reached a new 52-week low on Wednesday . The stock traded as low as $3.48 and last traded at $3.48, with a volume of 106,723 shares traded. The stock had previously closed at $3.95.
Several research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Oppenheimer Holdings Inc. lifted their target price on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a research report on Tuesday. Citigroup Inc. downgraded shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $7.00 to $4.50 in a research report on Tuesday. Leerink Swann cut shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $10.00 to $4.00 in a report on Monday. Finally, Cantor Fitzgerald restated a “buy” rating and set a $14.00 price target on shares of Mirna Therapeutics in a report on Friday, May 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $8.10.
The company’s market capitalization is $62.92 million. The company has a 50 day moving average of $4.21 and a 200-day moving average of $4.36.
Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.